Golimumab for iv use 1mg
Products billed under this code include Simponi Aria.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Simponi Aria.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Simponi Aria | Janssen Biotech, Inc. | 57894-0350-01 | 50 | $548.90 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $10.978 | −$0.057 | 1 MG | Golimumab for iv use 1mg | v1, posted September 17, 2026 |
| 3Q26 | $11.035 | −$0.252 | 1 MG | Golimumab for iv use 1mg | v1, posted September 15, 2026 |
| 2Q26 | $11.287 | −$0.344 | 1 MG | Golimumab for iv use 1mg | v1, posted September 15, 2026 |
| 1Q26 | $11.631 | +$0.592 | 1 MG | Golimumab for iv use 1mg | v1, posted September 15, 2026 |
| 4Q25 | $11.039 | +$0.01 | 1 MG | Golimumab for iv use 1mg | v1, posted September 8, 2026 |
| 3Q25 | $11.029 | +$0.26 | 1 MG | Golimumab for iv use 1mg | v1, posted March 10, 2026 |
| 2Q25 | $10.769 | +$0.233 | 1 MG | Golimumab for iv use 1mg | v1, posted March 10, 2026 |
| 1Q25 | $10.536 | −$0.564 | 1 MG | Golimumab for iv use 1mg | v1, posted December 19, 2025 |
| 4Q24 | $11.10 | −$0.27 | 1 MG | Golimumab for iv use 1mg | v1, posted June 11, 2025 |
| 3Q24 | $11.37 | −$0.431 | 1 MG | Golimumab for iv use 1mg | v1, posted June 11, 2025 |
| 2Q24 | $11.801 | −$0.54 | 1 MG | Golimumab for iv use 1mg | v1, posted March 11, 2025 |
| 1Q24 | $12.341 | −$0.59 | 1 MG | Golimumab for iv use 1mg | v1, posted December 19, 2024 |
| 4Q23 | $12.931 | −$0.356 | 1 MG | Golimumab for iv use 1mg | v1, posted October 10, 2024 |
| 3Q23 | $13.287 | −$0.562 | 1 MG | Golimumab for iv use 1mg | v1, posted June 5, 2024 |
| 2Q23 | $13.849 | +$0.002 | 1 MG | Golimumab for iv use 1mg | v1, posted February 23, 2024 |
| 1Q23 | $13.847 | −$0.233 | 1 MG | Golimumab for iv use 1mg | v1, posted December 6, 2023 |
| 4Q22 | $14.08 | −$0.609 | 1 MG | Golimumab for iv use 1mg | v1, posted June 22, 2023 |
| 3Q22 | $14.689 | −$0.325 | 1 MG | Golimumab for iv use 1mg | v1, posted June 9, 2023 |
| 2Q22 | $15.014 | −$1.054 | 1 MG | Golimumab for iv use 1mg | v1, posted December 14, 2022 |
| 1Q22 | $16.068 | −$0.75 | 1 MG | Golimumab for iv use 1mg | v1, posted June 8, 2022 |
| 4Q21 | $16.818 | −$0.138 | 1 MG | Golimumab for iv use 1mg | v1, posted June 2, 2022 |
| 3Q21 | $16.956 | −$0.194 | 1 MG | Golimumab for iv use 1mg | v1, posted June 2, 2022 |
| 2Q21 | $17.15 | −$0.974 | 1 MG | Golimumab for iv use 1mg | v1, posted March 1, 2022 |
| 1Q21 | $18.124 | – | 1 MG | Golimumab for iv use 1mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.